Jeyabalan Jeyaram Bharathi, Pandi A Vignesh, Veintramuthu Sankar, Sivasamy Ramasamy, Dhanasekaran Muralikrishnan, Justin Antony
Department of Pharmacology, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Ooty, Nilgiris, 643 001, Tamilnadu, India.
Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, 641004, Tamil Nadu, India.
Neurol Sci. 2025 Aug 26. doi: 10.1007/s10072-025-08421-2.
Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative disorders globally, each characterized by distinct pathological hallmarks; primarily tau neurofibrillary tangles and amyloid-beta plaques in AD, and alpha-synuclein (α-Syn) Lewy bodies in PD. However, evidence suggests a complex interplay between these proteins, particularly α-Syn and tau, which may contribute to the progression of both diseases. Recent observations demonstrate the co-occurrence of α-Syn and tau pathologies in both AD and PD patients. At the molecular level, both proteins exhibit prion-like propagation properties and can undergo cross-seeding, where one misfolded protein species induces the misfolding, aggregation of the other and increasing neurotoxicity. These proteins also share common post-translational modifications, cellular clearance mechanisms, and are influenced by similar microenvironmental factors that favor protein aggregation. This review explores the potential mechanisms by which α-Syn in PD may influence tau pathology, potentially exacerbating AD like disease progression that may potentially contribute to cognitive decline in PD. This review also delves into the underlying molecular pathways, such as prion-like propagation, cross-seeding, and inflammatory responses that could mediate this interaction, leading to enhanced neurodegeneration in comorbid cases. Further, various clinical implications of proteins' interplay, relevance to mixed neurodegenerative phenotypes, and potential therapeutic strategies targeting both α-Syn and tau pathologies have also been discussed in this manuscript.
阿尔茨海默病和帕金森病是全球最常见的神经退行性疾病,每种疾病都有独特的病理特征;在阿尔茨海默病中主要是tau神经原纤维缠结和β-淀粉样蛋白斑块,而在帕金森病中是α-突触核蛋白(α-Syn)路易小体。然而,有证据表明这些蛋白质之间存在复杂的相互作用,特别是α-Syn和tau,这可能导致两种疾病的进展。最近的观察表明,α-Syn和tau病理在阿尔茨海默病和帕金森病患者中同时出现。在分子水平上,这两种蛋白质都表现出朊病毒样的传播特性,并且可以进行交叉播种,即一种错误折叠的蛋白质物种诱导另一种蛋白质错误折叠、聚集并增加神经毒性。这些蛋白质还具有共同的翻译后修饰、细胞清除机制,并受到有利于蛋白质聚集的类似微环境因素的影响。本综述探讨了帕金森病中的α-Syn可能影响tau病理的潜在机制,这可能会加剧类似阿尔茨海默病的疾病进展,进而可能导致帕金森病患者的认知衰退。本综述还深入研究了潜在的分子途径,如朊病毒样传播、交叉播种和炎症反应,这些途径可能介导这种相互作用,导致合并病例中神经退行性变加剧。此外,本文还讨论了蛋白质相互作用的各种临床意义、与混合神经退行性表型的相关性以及针对α-Syn和tau病理的潜在治疗策略。